83 related articles for article (PubMed ID: 8669848)
41. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
42. Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen.
Strissel PL; Ellmann S; Loprich E; Thiel F; Fasching PA; Stiegler E; Hartmann A; Beckmann MW; Strick R
Int J Cancer; 2008 Dec; 123(12):2871-9. PubMed ID: 18814240
[TBL] [Abstract][Full Text] [Related]
43. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
[TBL] [Abstract][Full Text] [Related]
45. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients.
van der Hoek J; van der Lelij AJ; Feelders RA; de Herder WW; Uitterlinden P; Poon KW; Boerlin V; Lewis I; Krahnke T; Hofland LJ; Lamberts SW
Clin Endocrinol (Oxf); 2005 Aug; 63(2):176-84. PubMed ID: 16060911
[TBL] [Abstract][Full Text] [Related]
46. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.
Anderson E; Ferguson JE; Morten H; Shalet SM; Robinson EL; Howell A
Eur J Cancer; 1993; 29A(2):209-17. PubMed ID: 8422285
[TBL] [Abstract][Full Text] [Related]
47. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues.
Pollak M
Digestion; 1996; 57 Suppl 1():29-33. PubMed ID: 8813463
[TBL] [Abstract][Full Text] [Related]
48. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.
Pollak M; Costantino J; Polychronakos C; Blauer SA; Guyda H; Redmond C; Fisher B; Margolese R
J Natl Cancer Inst; 1990 Nov; 82(21):1693-7. PubMed ID: 2231756
[TBL] [Abstract][Full Text] [Related]
49. Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy.
Peyrat JP; Révillion F; Bonneterre J
Br J Cancer; 1998 May; 77(10):1669-71. PubMed ID: 9635846
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.
Boccardo F; Canobbio L; Resasco M; Decensi AU; Pastorino G; Brema F
J Cancer Res Clin Oncol; 1990; 116(5):503-6. PubMed ID: 2229142
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of the somatostatin analogue somatuline in refractory small-cell lung carcinoma.
Cotto C; Quoix E; Thomas F; Henane S; Trillet-Lenoir V
Ann Oncol; 1994 Mar; 5(3):290-1. PubMed ID: 8186178
[No Abstract] [Full Text] [Related]
52. The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer.
Paterson AG; Turkes A; Groom GV; Webster DJ
Eur J Cancer Clin Oncol; 1983 Jul; 19(7):919-22. PubMed ID: 6684048
[TBL] [Abstract][Full Text] [Related]
53. The role of somatostatin analogs in the management of medullary thyroid carcinoma.
Lupoli GA; Fonderico F; Fittipaldi MR; Colarusso S; Panico A; Cavallo A; Di Micco L; Lupoli G
J Endocrinol Invest; 2003; 26(8 Suppl):72-4. PubMed ID: 15233217
[No Abstract] [Full Text] [Related]
54. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
Pollak M; Gallant K; Poisson R; Harris A
Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585
[TBL] [Abstract][Full Text] [Related]
55. The salubrious effect of tamoxifen [correction of Tamaxifen] on serum marker enzymes, glycoproteins, and lysosomal enzymes level in breast cancer woman.
Thangaraju M; Rameshbabu J; Vasavi H; Ilanchezhian S; Vinitha R; Sachdanandam P
Mol Cell Biochem; 1998 Aug; 185(1-2):85-94. PubMed ID: 9746215
[TBL] [Abstract][Full Text] [Related]
56. Plasma proteomics analysis of tamoxifen resistance in breast cancer.
Majidzadeh-A K; Gharechahi J
Med Oncol; 2013 Dec; 30(4):753. PubMed ID: 24158757
[TBL] [Abstract][Full Text] [Related]
57. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study.
Canobbio L; Boccardo F; Cannata D; Gallotti P; Epis R
Cancer; 1992 Feb; 69(3):648-50. PubMed ID: 1346097
[TBL] [Abstract][Full Text] [Related]
58. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review.
Kasprzak A; Geltz A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540191
[TBL] [Abstract][Full Text] [Related]
59. Somatostatin and Somatostatin Receptors in Tumour Biology.
Kumar U
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203605
[TBL] [Abstract][Full Text] [Related]
60. Estrogens and selective estrogen receptor modulators in acromegaly.
Duarte FH; Jallad RS; Bronstein MD
Endocrine; 2016 Nov; 54(2):306-314. PubMed ID: 27704479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
